Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Open Label Phase Ia/Ib, Multicenter/Multiregional, Dose Escalation Study of BI 765883 Administered Intravenously as Monotherapy and in Combination With Gemcitabine and Nab-paclitaxel in Unselected Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) or Patients With PDAC Who Have Relapsed After Post-surgery Adjuvant Therapy

NCT06528093 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06528093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06528093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Open Label Phase Ia/Ib, Multicenter/Multiregional, Dose Escalation Study of BI 765883 Administered Intravenously as Monotherapy and in Combination With Gemcitabine and Nab-paclitaxel in Unselected Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) or Patients With PDAC Who Have Relapsed After Post-surgery Adjuvant Therapy
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Terminated
Start date
October 16, 2024
Completion date
June 19, 2025
Enrollment
8 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma